Depression Clinical Trial
— CABINOfficial title:
Effects of a 14-day Combined Antidepressant and Behavioural Intervention on Emotional Cognition in Healthy Volunteers Experiencing Low Mood
NCT number | NCT05627154 |
Other study ID # | Cabin |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 28, 2021 |
Est. completion date | November 17, 2023 |
Verified date | May 2024 |
Source | University of Oxford |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A body of evidence from both animal and human research suggests that antidepressant drugs may induce early changes in emotional processing that interact with environmental factors to produce a later change in mood. This experimental medicine study will examine the effect of citalopram on emotional cognition under different environmental conditions (as manipulated by the presence or absence of behavioural activation training). Participants will be administered either citalopram or placebo over the course of two weeks. Citalopram will be taken either alone or in combination with behavioural activation training.
Status | Completed |
Enrollment | 134 |
Est. completion date | November 17, 2023 |
Est. primary completion date | November 17, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Aged 18-65 years inclusive - Resident in the UK for the duration of the study - Fluent in English - Normal or corrected-to-normal vision - Experiencing subjective low mood (score of 10 or above on the BDI-II) - Experiencing low activity levels (self-reported) - Willing and able to give informed consent for participation in the research - Access to a computer or laptop with a functioning keyboard and a reliable internet connection Exclusion Criteria: - Antidepressant treatment or medication prescribed to treat depression/low mood, currently or in the last six months - Current psychological therapy of any kind - Current or past probable diagnosis of psychosis, bipolar disorder, OCD, PTSD, substance abuse disorder or any eating disorder, as indicated by the SCID-5 - Current or past diagnosis of any personality disorder (e.g. borderline personality disorder) according to self-report - Judged to be at clinical high risk of suicide - Past suicide attempt - Current or past hospitalisation for mental health reasons - 1st degree relative with diagnosis of bipolar disorder - Diagnosis of a developmental disorder (e.g. ASD, ADHD, Tourette's syndrome, severe learning disability) according to self-report; this excludes cases of mild dyslexia or dyscalculia where in the opinion of the study team such difficulties would not interfere with the performance of the tasks required in this study - Diagnosis of a neurological disorder (e.g. epilepsy, MS) according to self-report - Score of >30 on the BDI-II - Current use of medication that might interact with the effects of citalopram (except for the contraceptive pill) - Known contraindication to citalopram including: past allergic reaction to citalopram or any other medicines, diagnosis of a cardiovascular condition, glaucoma, type 1 or type 2 diabetes, diagnosis of epilepsy, undergoing electroconvulsive treatment (ECT), or current use of any other medication that is associated with prolonged QT-interval - Any other current or past medical conditions which in the opinion of the study medic may interfere with the safety of the participant or the scientific integrity of the study - Heavy use of cigarettes (smoke > 20 cigarettes per day) - Heavy use of caffeine (drink > 4 250ml cups/cans of coffee/energy drinks per day) - Severely underweight or overweight in a manner that renders them unsuitable for the study in the opinion of the study medic - Lactose intolerance (due to the study involving administration of a lactose placebo tablet) - Pregnancy (as determined by urine pregnancy test taken during the Part 2 screening visit), breast feeding or plans to become pregnant - Participation in an ETB study in the past 6 months - Participation in another drug study in the past 3 months |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Neurosciences Building, Warneford Hospital | Oxford | Oxfordshire |
Lead Sponsor | Collaborator |
---|---|
University of Oxford | National Institute for Health Research, United Kingdom |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in daily mood | Fluctuations in daily mood measures using a Mood Zoom format, comprising six items on a 7-point Likert scale | 7 days pre-intervention compared to last 7 days of intervention | |
Primary | Changes in emotional cognition | Accuracy and reaction times on computer-based measures of emotional cognition (facial expression recognition task, emotional word categorisation task, emotional word recall task, emotional word recognition task). | Pre-intervention and 13-15 days after the start of the intervention | |
Secondary | Changes in reward processing | Accuracy, consistency, reaction times, monetary wins and losses, learning rate and decision temperature on the Probabilistic Instrumental Learning Task. | Pre-intervention and 13-15 days after the start of the intervention | |
Secondary | Changes in motor activity | Acceleration, light and temperature data measured at 25 Hz using GENEActiv actigraphy watches | 7 days pre-intervention compared to last 7 days of intervention | |
Secondary | Changes in salivary cortisol | Waking cortisol levels assayed using a Salimetrics Salivary Cortisol ELISA Kit from 6 saliva samples (3 pre- and 3 post-intervention) collected using Sarstedt SalivetteĀ® Cortisol tubes | Pre-intervention and 13-14 days after the start of the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |